Swaminathan Arun 4

What Happened

• Swaminathan Arun, CEO of Coya Therapeutics (COYA), was granted a derivative equity award covering 293,983 shares on 2026-01-22. The reported acquisition price is $0.00, indicating no cash paid at grant as reported. The award is subject to vesting and other plan terms.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (timely filed).
• Transaction type/code: Grant/Award (A) — derivative security reported.
• Shares/units granted: 293,983 (reported at $0.00).
• Vesting: Shares underlying the option vest in monthly installments over the next 36 months, contingent on continued service.
• Change-in-control: Upon a change in control, the shares underlying the option vest and the option becomes immediately exercisable per the Issuer's 2021 Equity Incentive Plan (as amended Nov 17, 2022).
• Shares owned after transaction: Not specified in the filing.

Context

• This was an equity award grant (derivative) rather than an open-market purchase or sale; such grants are common for executive compensation and are typically subject to vesting conditions. The filing does not indicate a cash exercise or sale of shares — it documents the grant and vesting schedule.